1. bookVolume 57 (2019): Issue 2 (June 2019)
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
access type Open Access

Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy – a retrospective cohort study

Published Online: 20 Jun 2019
Volume & Issue: Volume 57 (2019) - Issue 2 (June 2019)
Page range: 141 - 150
Received: 10 Oct 2018
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction. Circulating autoantibodies against phospholipase A2 receptor (anti-PLA2R) are recognized as key elements in the pathogenesis of idiopathic membranous nephropathy. In current clinical practice, they are increasingly gaining attention as novel tools for diagnosis and disease monitoring. We investigated the diagnostic and prognostic utility of anti-PLA2R antibody measurements in Greek patients with biopsy-proven membranous nephropathy.

Methods. Anti-PLA2R levels were measured in serum samples from 33 patients at diagnosis using ELISA and were associated with treatment outcome. Moreover, serial anti-PLA2R measurements were performed in 15 patients under different clinical conditions and level alterations were correlated with disease activity.

Results. Positive anti-PLA2R antibodies at diagnosis were found in 16 of 33 patients (48.5%). Anti-PLA2R levels were independently associated with the achievement of complete remission of nephrotic syndrome after immunosuppressive treatment compared to partial remission (p = 0.02, R2 = 0.265, 95%CI -0.019 to -0.0003). Higher detectable antibody levels at diagnosis were correlated with higher proteinuria levels (r = 0.813, p = 0.0001, 95%CI 0.532 to 0.933) and lower eGFR at the end of follow-up (r = -0.634, p = 0.0083, 95%CI -0.86 to -0.202). Serial antibody measurements during follow-up showed that anti-PLA2R titers were significantly reduced at the end of treatment after complete remission was achieved, remained low under sustained clinical remission, and increased during relapse.

Conclusions. Our findings confirm the usefulness of anti-PLA2R measurements in the diagnosis of idiopathic membranous nephropathy. Low levels of anti-PLA2R antibodies at diagnosis are predictive of complete remission of nephrotic syndrome following immunosuppressive treatment. Serial anti-PLA2R measurements correlate well with clinical status throughout the follow-up period and could be used routinely for monitoring of disease activity and treatment planning.

Keywords

1. OBRISCA B., ISMAIL G., JURUBITA R., BASTON C., ANDRONESI A., MIRCESCU G. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy. Biomed Res Int. 2015;2015:249740.10.1155/2015/249740463037226576418Search in Google Scholar

2. BECK L.H. JR., BONEGIO R.G., LAMBEAU G., BECK D.M., POWELL D.W., CUMMINS T.D., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.10.1056/NEJMoa0810457276208319571279Search in Google Scholar

3. SVOBODOVA B., HONSOVA E., RONCO P., TESAR V., DEBIEC H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839–44.10.1093/ndt/gfs43923223223Search in Google Scholar

4. HOFSTRA J.M., BECK L.H. JR., BECK D.M., WETZELS J.F., SALANT D.J., Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286–91.10.2215/CJN.07210810310992321474589Search in Google Scholar

5. SEGARRA-MEDRANO A., JATEM-ESCALANTE E., CARNICER-CÁCERES C., AGRAZ-PAMPLONA I., SALCEDO M.T., VALTIERRA N., et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia. 2014;34(4):491-7.Search in Google Scholar

6. KANIGICHERLA D., GUMMADOVA J., MCKENZIE E.A., ROBERTS S.A., HARRIS S., NIKAM M., et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83(5):940–8.10.1038/ki.2012.48623364522Search in Google Scholar

7. BECK L.H. JR, FERVENZA F.C., BECK D.M., BONEGIO R.G., MALIK F.A., ERICKSON S.B., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543-50.10.1681/ASN.2010111125314870921784898Search in Google Scholar

8. RAMACHANDRAN R., KUMAR V., SINGH N., KATARUKA M., RATHI M.,KOHLI H.S., et al. Utility of determining autoantibodies to M-type phospholipase A2 receptor in diagnosing primary membranous nephropathy: An ideal setting. Indian J Nephrol. 2017;27(5):413-415.10.4103/ijn.IJN_165_16559042528904444Search in Google Scholar

9. TOMAS N.M., BECK L.H. JR, MEYER-SCHWESINGER C., SEITZ-POLSKI B., MA H., ZAHNER G., et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–87.10.1056/NEJMoa1409354427875925394321Search in Google Scholar

10. KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int 2012;2 (Suppl 2):186-197.Search in Google Scholar

11. DU Y., LI J., HE F., LV Y., LIU W., WU P., et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis. PLoS One. 2014;9(8):e104936.10.1371/journal.pone.0104936413815425136841Search in Google Scholar

12. HOFSTRA J.M., DEBIEC H., SHORT C.D., PELLÉ T., KLETA R., MATHIESON P.W., et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735–43.10.1681/ASN.2012030242345846522956816Search in Google Scholar

13. BRENCHLEY P.E. Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of anti-phospholipase a2 receptor autoantibodies. J Am Soc Nephrol. 2015;26(10):2308-11.10.1681/ASN.2015020181458770825804283Search in Google Scholar

14. VAN DE LOGT A.E., HOFSTRA J.M., WETZELS J.F. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int. 2015;87(6):1263-4.10.1038/ki.2015.3426024039Search in Google Scholar

15. GOPALAKRISHNAN N., ABEESH P., DINESHKUMAR T., MURUGANANTH S., SAKTHIRAJAN R., RAMAN G.S., et al. Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: A single center experience. Indian J Nephrol. 2016;26(4):257-61.10.4103/0971-4065.160334496468527512297Search in Google Scholar

16. LI X., WEI D., ZHOU Z., WANG B., XU Y., PAN J., et al. Anti-PLA2R Antibodies in Chinese patients with membranous nephropathy. Med Sci Monit. 2016;22:1630-6.10.12659/MSM.896090Search in Google Scholar

17. OH Y.J., YANG S.H., KIM D.K., KANG S.W., KIM Y.S. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One. 2013;8(4):e62151.10.1371/journal.pone.0062151363739023637987Search in Google Scholar

18. HILL P.A., MCRAE J.L., DWYER K.M. PLA2R and membranous nephropathy: A 3-year prospective Australian study. Nephrology (Carlton). 2016;21(5):397-403.10.1111/nep.1262426369693Search in Google Scholar

19. ARDALAN M., GHAFARI A., HAMZAVI F., NASRI H., BARADARAN B., MAJIDI J., et al. Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population. J Nephropath. 2013;2(4):241-8.Search in Google Scholar

20. QIN W., BECK L.H. JR, ZENG C., CHEN Z., LI S., ZUO K., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137–43.10.1681/ASN.2010090967310373321566055Search in Google Scholar

21. RUGGENENTI P., DEBIEC H., RUGGIERO B., CHIANCA A., PELLÉ T., GASPARI F., et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58.10.1681/ASN.2014070640458768825804280Search in Google Scholar

22. TIMMERMANS S.A., ABDUL HAMID M.A., COHEN TERVAERT J.W., DAMOISEAUX J.G., VAN PAASSEN P.; LIMBURG RENAL REGISTRY. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am J Nephrol. 2015;42(1):70-7.10.1159/00043723626344651Search in Google Scholar

23. POURCINE F., DAHAN K., MIHOUT F., CACHANADO M., BROCHERIOU I., DEBIEC H., et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS One. 2017;12(3):e0173201.10.1371/journal.pone.0173201533629428257452Search in Google Scholar

24. HOXHA E., THIELE I., ZAHNER G., PANZER U., HARENDZA S., STAHL R.A. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357-66.10.1681/ASN.2013040430403336524610926Search in Google Scholar

25. RADICE A., TREZZI B., MAGGIORE U., PREGNOLATO F., STELLATO T., NAPODANO P., et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev. 2016;15(2):146-54.10.1016/j.autrev.2015.10.00426527329Search in Google Scholar

26. BECH A.P., HOFSTRA J.M., BRENCHLEY P.E., WETZELS J.F. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386–92.10.2215/CJN.10471013412340225035272Search in Google Scholar

27. LIU Y., LI X., MA C., WANG P., LIU J., SU H., et al. Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients. Clin Chim Acta. 2018;476:9-14.10.1016/j.cca.2017.11.00629126817Search in Google Scholar

28. TAMPOIA M., MIGLIUCCI F., VILLANI C., ABBRACCIAVENTO L., ROSSINI M., FUMARULO R., et al. Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy. J Nephrol. 2018;31(6):899-905.10.1007/s40620-018-0533-z30187382Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo